RELCH

Across TCGA pan-cancer cohorts, RELCH mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RELCH data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RELCH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RELCH expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where RELCH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.845	0.414	.011	12	view →
PDAC	DFS	Tertile	III,IV	0.768	0.374	.019	5	view →
GBM	DFS	Median	All	0.842	0.656	.024	4	view →
LUAD	OS	Tertile	II,III,IV	0.277	0.762	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RELCH–CCRCC (OS)

Open the CCRCC breakdown →